Search results
Showing 16 to 30 of 277 results for coronavirus
NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .
Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19...
risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose...
systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and...
In development Reference number: GID-TA11224 Expected publication date: TBC
Awaiting development Reference number: GID-TA11226 Expected publication date: TBC
Awaiting development Reference number: GID-TA11227 Expected publication date: TBC
efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific...